Libtayo®(西米普利单抗)获欧盟CHMP推荐批准:所有已获批癌症类型均可采用更新给药方案
Libtayo®(西米普利单抗)获欧盟CHMP推荐批准:所有已获批癌症类型均可采用更新给药方案
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.